Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Edwards’ Sapien 3 With The Alterra Prestent For Pulmonary Regurgitation

Executive Summary

The new device combines Edwards’ market-leading Sapien 3 transcatheter heart valve with its Alterra adaptive prestent device to treat patients with severe pulmonary regurgitation due to congenital valve defects.

You may also be interested in...



Edwards Stays On Track For ‘Mid-Teens’ TAVR Growth In 2021

Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.

FDA Approves Two New Indications For Edwards’ Sapien 3 TAVR System

Sapien 3 is now indicated to treat failed right ventricular outflow tract conduits, surgical bioprosthetic pulmonary valves and transcatheter aortic valves.

CMR Signs Deal With J&J To Bring Robots To Europe And South America

CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel